PHARMACY

Curemark gets nod to start late-stage trial for ADHD drug

BY Alaric DeArment

RYE, N.Y. The Food and Drug Administration has approved a late-stage clinical trial of a drug for attention deficit hyperactivity disorder.

Curemark said the FDA cleared its application to run a phase 3 trial of CM-4612 in patients with ADHD. The company is currently conducting a phase 3 trial of CM-AT, a treatment for autism in children.

“We are very excited to have received [clearance] from the FDA so that we can move forward with clinical trials to study CM-4612,” Curemark CEO Joan Fallon said. “Curemark hopes to have the first physiologically based medication to address ADHD, in lieu of the current psychotropic and stimulant treatments.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Sanofi, Scripps Genomic Medicine form partnership

BY Alaric DeArment

BRIDGEWATER, N.J. French drug maker Sanofi-Aventis and a division of San Diego-based nonprofit community health system Scripps Health will work together in the field of personalized medicine.

The two companies announced Tuesday the partnership between Sanofi and Scripps Genomic Medicine, under which Sanofi-Aventis Research & Development will fund up to three grants per year for research proposals from Scripps investigators.

“Our alliance with Sanofi-Aventis exemplifies the ideal collaboration between the pharmaceutical industry and nonprofit research community,” Scripps Health chief academic officer Eric Topol said. “The partnership aims to foster an environment of open scientific exchange in genomic medicine that we hope will translate to new discoveries to benefit patients while establishing a collaborative approach to drug development.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Revenue, profit rise for Watson in Q2

BY Alaric DeArment

MORRISTOWN, N.J. Generic drug maker Watson Pharmaceuticals posted strong sales for second quarter 2010, according to an earnings report.

Revenue for the quarter were $875.3 million, a 29% increase over second quarter 2009. Profit was $102.8 million, a 22% increase over last year.

“The second quarter was one of solid financial growth, consistent performance and continued progress against the strategies that will ensure growth of Watson’s global business,” Watson president and CEO Paul Bisaro said. “We continue to emphasize growing our businesses through product development and portfolio and market expansion.”

Generic drugs had global sales of $560.8 million, compared with $393.8 million in second quarter 2009. For the first six months of the year, generics sales were $1.09 billion, compared with $789 million during the same period last year.

Sales for Watson’s branded drugs segment were $76.9 million, compared with $97.6 million in second quarter 2009. The decrease was due mostly to Watson handing over marketing rights for the iron deficiency drug Ferrlecit (sodium ferric gluconate) to French drug maker Sanofi-Aventis in December.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES